Text Size

Development of Predictive Biomarkers and Novel Approached to Therapy in Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by National University Hospital, Singapore.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
National University Hospital, Singapore
ClinicalTrials.gov Identifier:
NCT01051492
First received: January 15, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted
  Purpose

Breast cancer is a common malignancy world-wide, and is the commonest female malignancy in Singapore, with rising trends in incidence over the last 2 decades. While there have been improvements in treatment, mortality from breast cancer remains significant. Development of biomarkers to predict treatment response and toxicity to anti-cancer agents can rationalize the choice of therapy for the individual patients to optimize treatment outcome and to reduce unnecessary toxicities. Development of novel therapies or novel approaches to therapy is also critical to improve the treatment armamentarium in breast cancer. These research strategies will have an significant impact on breast cancer treatment both in Singapore as well as globally.


Condition
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Cross-Sectional

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National University Hospital, Singapore:

Study Start Date: January 2010
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Any individual who has been diagnosed with breast cancer

Criteria

Inclusion Criteria:

This program will recruit mainly cancer patients, predominantly breast cancer patients. The exact inclusion criteria will vary between each individual study. Each individual component study will be submitted to DSRB for separate approval, along with the study protocol and patient informed consent sheet.

Exclusion Criteria:

The exact exclusion criteria will vary between each individual study. Each individual component study will be submitted to DSRB for separate approval, along with the study protocol and patient informed consent sheet.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01051492

Contacts
Contact: Soo Chin Lee, MBBS, MRCP 65 6772 4629 soo_chin_lee@nuhs.edu.sg

Locations
Singapore
National University Hospital Singapore Not yet recruiting
Singapore, Singapore
Contact: Soo Chin Lee, MBBS, MRCP     65 6772 4629     soo_chin_lee@nuhs.edu.sg    
Principal Investigator: Soo Chin Lee, MBBS, MRCP            
Sponsors and Collaborators
National University Hospital, Singapore
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT01051492     History of Changes
Other Study ID Numbers: BR07/30/09
Study First Received: January 15, 2010
Last Updated: January 15, 2010
Health Authority: Singapore: Domain Specific Review Boards

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on May 22, 2013